ArticleHuman vaccines & immunotherapeutics2021
Impact of population aging on the burden of vaccine-preventable diseases among older adults in the United States.
Article in Human vaccines & immunotherapeutics, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 33 papers, 2 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
33 citing papers in PubMed, 2 syntheses or guidelines pooled it, 54 citations in OpenAlex.
- Incorporating human dynamic populations in models of infectious disease transmission: a systematic review.BMC infectious diseases · 2022Pooled it
- The burden of seasonal influenza in Italy: A systematic review of influenza-related complications, hospitalizations, and mortality.Influenza and other respiratory viruses · 2022Pooled it
- Addressing racial inequality and its effects on vaccination rate: A trial comparing a pharmacist and peer educational program (MOTIVATE) in diverse older adults.Journal of managed care & specialty pharmacy · 2023Trial
- Global, regional, and national burden of influenza-associated lower respiratory infections, 1990-2021: a systematic analysis from the Global Burden of Disease Study 2021.BMC infectious diseases · 2026Article
- Utilizing age-friendly cities and communities to support access to vaccination, vision, hearing and oral healthcare.Frontiers in aging · 2026Article
- Article
- Attitudes toward and regional utilization of age-specific vaccinations from the age of 60 in Saxony-Anhalt.Research in health services & regions · 2025Article
- A cost-benefit analysis of adult immunization programs across ten countries: Modeling the socioeconomic value of immunization for older populations compared to no vaccination.Human vaccines & immunotherapeutics · 2025Article
- Burden of Pneumococcal Disease and Adult Vaccination Landscape: An Overview with Data and Policy Insights from Türkiye.Infectious diseases & clinical microbiology · 2025Review
- Damage response signaling by the extracellular adenosine pathway: control of infection outcome during host aging.mSphere · 2025Review
- Stakeholder readiness in the evolving adult vaccine market.iScience · 2025Article
- Rapid aging of influenza epidemics in China from 2005/06 to 2016/17: A population-based study.Infectious Disease Modelling · 2025Article
- Health care resource use and costs associated with adult pneumococcal disease in the United States from 2017 to 2019, stratified by age and health risk: a retrospective cohort study.Frontiers in public health · 2025Article
- Understanding Influenza Vaccine Clinical Performance: A Podcast.Advances in therapy · 2025Review
- Advanced immunology in aging population: unveiling the complexities of vaccine responsiveness.Frontiers in aging · 2025Review
- Respiratory Virus Vaccines: Pathways to Recommendations and Enhanced Coverage for At-Risk Populations.Infectious diseases and therapy · 2025Article
- Role of new vaccinators/pharmacists in life-course vaccination.Annals of medicine · 2024Review
- The Annual Economic Burden of Respiratory Syncytial Virus in Adults in the United States.The Journal of infectious diseases · 2024Article
- Review
- Cost of illness of the vaccine-preventable diseases influenza, herpes zoster and pneumococcal disease in France.European journal of public health · 2024Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors at 2 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Despite vaccination recommendations, the burden of vaccine-preventable diseases remains high in older adults in the United States (US), contributing to substantial morbidity, mortality, and health care resource use and costs. To adequately plan for health care resource needs and to help inform vaccination policies, burden of disease projections that account for population aging over the coming decades are needed. As a first step, this exploratory study projects the burden of influenza, pertussis, herpes zoster, and pneumococcal disease in adults aged 50 y and older in the US, using a population-based modeling framework with separate decision trees for each vaccine-preventable disease. The model uses projected population estimates from the US Census Bureau to account for changes in the US population over time and then calculates expected numbers of cases and associated costs for each disease, keeping current estimates of age-specific disease incidence, vaccine coverage, and efficacy constant over time. This approach was used to focus the exploratory analysis on the burden of disease that may be expected due to population changes alone, assuming that all else remains unchanged. Due to population growth and the shifting age distribution over the next 30 y, the annual societal economic burden for the four vaccine-preventable diseases is projected to increase from approximately $35 billion to $49 billion, resulting in cumulative costs of approximately $1.3 trillion, as well as more than 1 million disease-related deaths. Given such notable burden, further efforts to increase vaccination coverage and effectiveness in older adults are needed.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.